Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037695 | 0.81 | TSHR (0.39) | — | |
| SCHEMBL26743081 | 0.78 | APLNR (0.40) | APLNR | |
| SCHEMBL31566400 | 0.78 | APLNR (0.40) | APLNR | |
| SCHEMBL31392865 | 0.77 | APLNR (0.40) | APLNR | |
| SCHEMBL26621129 | 0.75 | APLNR (0.33) | APLNR | |
| SCHEMBL15300270 | 0.75 | GABBR2 (0.36) | — | |
| SCHEMBL31501537 | 0.72 | APLNR (0.54) | APLNR | |
| SCHEMBL24707461 | 0.72 | APLNR (0.39) | APLNR | |
| SCHEMBL31739278 | 0.69 | — | — | |
| SCHEMBL31507685 | 0.68 | GABRA5 (0.34) | APLNRGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-12351581-B2 | Compounds for FGFR inhibition | COGENT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250066352-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066352-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | APLNR 1247/4885GABRA5 1263/4885 |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | APLNR 1247/4885GABRA5 1263/4885 |
| US-12351581-B2 | Compounds for FGFR inhibition | FGFR1, FGFR4, FGFR3 | APLNR 1247/4885GABRA5 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.